Galectin Therapeutics Inc.
GALT
Health Care
2
exclusion reasons
1 theme
Galectin Therapeutics Inc. is screened out under 2 exclusion reasons spanning 1 issue category.
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. It is a statement of values.
Galectin Therapeutics is a biotechnology company whose drug development pipeline relies on animal testing to advance its primary investigational compounds. The company’s lead drug candidates, including belapectin (GR-MD-02), are designed to inhibit galectin-3 proteins to treat fibrotic diseases. Preclinical research supporting these candidates, as cited in the company’s regulatory filings and clinical trial documents, explicitly references studies using animal models with genetic modifications, such as galectin-3 “knock-out” mice, to demonstrate therapeutic mechanisms and efficacy. This reliance on animal data is a standard, integral part of its research and development process for new pharmaceuticals.
The company’s clinical trial history, including a Phase 2 extension study (NCT02333955), notes that the rationale for its drug candidates is supported by prior research in animal models showing that genetic knockout of galectin-3 reduces structural deficits in organs like the kidney. This indicates animal testing is not incidental but foundational to its product development. As a clinical-stage biopharmaceutical firm with no marketed products, its entire value proposition is built on preclinical animal data to advance candidates toward human trials.
Galectin Therapeutics Inc. is a clinical-stage biotechnology company whose drug development pipeline is fundamentally dependent on animal testing. Its lead drug candidates, including belapectin (GR-MD-02) for NASH cirrhosis and other galectin-3 inhibitors, were discovered and validated using genetic knockout animal models. The company’s own SEC filings explicitly state that published data substantiating the role of galectin-3 in fibrosis “arises from gene knockout experiments in animal studies.” Its development process, as described in regulatory documents, requires the “completion of preclinical laboratory tests, animal studies, and formulation studies” before advancing to human trials. As a pharmaceutical research entity with no marketed products, its entire business model is predicated on animal-based pre-clinical research to satisfy regulatory requirements for investigational new drug applications.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.